Suzhou Bluehorse Therapeutics Co., Ltd.

This study tests a new treatment using a patient's own immune cells (called TILs) to prevent non-small cell lung cancer from returning after surgery. About 45 adults who have already had chemotherapy and surgery will be randomly assigned to receive either TILs plus standard care,…

This phase 2 trial tests a new treatment called LM103 TILs, made from a patient's own immune cells, for advanced melanoma that hasn't responded to standard therapies. About 92 adults will be randomly assigned to receive either the TIL therapy or standard care. The study aims to s…